Ramucirumab: A Novel Antiangiogenic Agent for Gastric Cancer and Gastroesophageal Junction Cancer
May 6th 2014Advanced gastric cancer and gastroesophageal junction cancers are highly aggressive cancers with poor prognosis and limited treatment options. The VEGF pathway has been one of the key signaling pathways under investigation for these cancers.